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Hepatitis E virus (HEV) infection is the leading cause of acute hepatitis worldwide 
and can develop into chronic infection in immunocompromised patients, promoting 
the development of effective antiviral therapies. In this study, we performed a 
screening of a library containing over 1,000 FDA-approved drugs. We have identified 
deptropine, a classical histamine H1 receptor antagonist used to treat asthmatic 
symptoms, as a potent inhibitor of HEV replication. The anti-HEV activity of 
deptropine appears dispensable of the histamine pathway, but requires the inhibition 
on nuclear factor-κB (NF-κB) activity. This further activates caspase mediated by 
receptor-interacting protein kinase 1 (RIPK1) to restrict HEV replication. Given 
deptropine being widely used in the clinic, our results warrant further evaluation of its 
anti-HEV efficacy in future clinical studies. Importantly, the discovery that NF-κB-
RIPK1-caspase pathway interferes with HEV infection reveals new insight of HEV-
host interactions. 




Acute liver inflammation is usually self-limiting upon elimination of the etiological 
agents. However, unresolved inflammation may lead to the development of chronic 
liver diseases and cancer. Hepatitis E virus (HEV) infection represents the most 
common cause for acute viral hepatitis (Crossan et al., 2014). It has caused many 
large hepatitis outbreaks, especially in resource-limited regions (Hakim et al., 2018). 
In the developing countries, the major clinical burden lies with the pregnant women 
population, which is usually caused by genotype 1 HEV. If no recovery from 
spontaneous clearance of the virus, these acutely infected patients will have high risk 
to develop liver failure and death. In western counties, chronic hepatitis E cases have 
been frequently reported in immunocompromised patients, in particular organ 
transplant recipients (Kamar et al., 2008). Genotype 3 and occasionally genotype 4 
HEV are the main causes of chronic infection. For the infection in these specific 
populations including pregnant women and organ transplantation patients, safe and 
effective antiviral treatment is evidently required.  
Besides supportive care, pegylated interferon alpha (PEG-IFNα) and ribavirin (Kamar 
et al., 2014) in particular have been explored in the clinic for treating some chronic 
HEV cases. Ribavirin is effective in general, but the failure of treatment has been 
frequently reported (Debing et al., 2016). However, the remaining challenges include 
that not all chronic HEV patients respond to ribavirin, the emerging of potential 
resistance strains and the substantial side effects that limit the applications in 
pregnant women, young children and elderly patients (Todt et al., 2016). Sofosbuvir, 
a clinically used direct-acting antiviral for treating hepatitis C virus (HCV) infection, 
has recently been proposed for treating HEV. However, mixed results were obtained 
from both experimental models and patients (Dao Thi et al., 2016; Kamar et al., 
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2017), and likely it is not very effective against HEV (Kamar et al., 2017). In parallel, 
various preclinical compounds, including nucleoside and non-nucleoside antiviral 
agents (Netzler et al., 2019), protein kinase-targeted compounds (Wang et al., 
2017a), inhibitors targeting mitochondrial metabolism (Qu et al., 2019), inhibitors of 
nucleotide synthesis (Wang et al., 2016) and natural compounds (Todt et al., 2018), 
are being investigated in experimental models. Given the pathogenic nature and the 
specific populations affected by HEV, we hypothesize that repurposing currently used 
drugs represents an effective approach to develop antiviral treatment that can readily 
benefit the patients.   
In this study, we screened a library of FDA-approved drugs. We identified deptropine, 
a traditional histamine receptor H1 antagonist used to treat asthmatic symptoms (de 
Vries et al., 2006; Schirm et al., 2002), as a potent inhibitor against HEV. 
Mechanistically, the anti-HEV activity of deptropine is dispensable of the histamine 
pathway, but requires the crosstalk between nuclear factor-κB (NF-κB) and caspase 
activity regulated by receptor-interacting protein kinase 1 (RIPK1). These results 
bears potential implications for the real-world treatment of HEV patients from 





2. Materials and methods 
2.1. Drug screening  
A commercially available library of FDA-approved drugs, the Prestwick chemical 
library (http://www.prestwickchemical.com/), was used. The screening was performed 
in a 96-well plate format with 10000 cells in each well. Compounds were solubilized 
at 1 mM in dimethyl sulfoxide (DMSO) and all compounds were diluted in culture 
media for a final concentration of 10 µM during screening.  
2.2. Cell culture models 
Multiple cell lines including human hepatoma Huh7.5 cell line, Hep3B cell line and 
human embryonic kidney epithelial HEK 293T cell line were kindly provided from 
Department of Viroscience, Erasmus Medical Center. These cell lines were cultured 
with Dulbecco’s modified Eagle medium (DMEM) (Lonza Biowhittaker, Verviers, 
Belgium) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS) 
(Hyclone, Lonan, Utah), 100 IU/mL penicillin, 100 µg/mL streptomycin. Mouse 
embryonic fibroblast (MEF) WT and NF-κB -/- cells were generated by Dr. A. 
Hoffmann (Signaling Systems Lab, Los Angeles, CA), and were grown in DMEM with 
10% FCS, 100 IU/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 20 
mM HEPES as described previously (Xu et al., 2017).  
For genotype 3 HEV models, Huh7.5, Hep3B, and 293T cell lines were 
electroporated with the subgenomic HEV RNA (p6 clone) coupled with a Gaussia 
luciferase reporter gene to establish the replication model (subgenomic replicon). 
Electroporation of the full-length p6 HEV genome was used to establish the infectious 
model, and more details have been described previously (Wang et al., 2017b). MEF 
cells were seeded in 96 well plate (1×104 per well) and were inoculated with cell 
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culture-produced HEV particles (1.5×106 HEV RNA copies/ml) for 48 hours before 
being subjected to qRT-PCR analysis.  
For HEV genotype 1 replicon model, Huh7.5 cells were electroporated with 
Sar55/S17/luc HEV RNA, and viral replication was detected by Gaussia luciferase 
activity (Xu et al., 2017). For HCV replicon model, Huh7.5 cells were electroporated with 
the subgenomic HCV bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET), and viral 
replication was monitored by measuring firefly luciferase activity (Pan et al., 2009). For 
rotavirus model, Caco2 cells were inoculated with simian rotavirus SA11. NF-κB, AP-1 
luciferase reporter cells were generated by transducing Huh7.5 cells with lentiviral 
vectors expressing the firefly luciferase gene under the control of the promoters 
containing the NF-κB, AP-1 motifs (Wang et al., 2017a), respectively (System 
Biosciences). 
2.3. Statistical analysis 
Statistical analysis was performed using the nonpaired, nonparametric test with 
Mann-Whitney test (GraphPad Prism version 5.01; GraphPad Software). P values < 






3.1. Screening of a Library of FDA-approved Drugs Identifies Deptropine as a 
potent Anti-HEV Agent 
To identify potential anti-HEV drug candidates, we employed a library of 1280 
compounds (95% are FDA-approved drugs). The initial screening was performed in a 
Huh7.5 cell-based genotype 3 HEV replicon model in which the 5’ portion of HEV 
ORF2 was replaced with the in-frame secreted form of Gaussia luciferase. Thus, 
accumulation of luciferase indicates viral replication, whereas the absence of the 
ORF2, which encodes the capsid protein precludes the propagation of novel viral 
particles. This model was treated with each compound at a concentration of 10 µM 
and the DMSO vehicle control for 48 hours (Fig. 1A). We found that some drugs 
inhibit but some promote, whereas the majority have no major effect on HEV 
replication-related luciferase activity (Fig. 1B). To exclude the possibility that the 
antiviral ability may be attributed to its cytotoxicity (Fig. S1), 38 drugs identified with 
more than 50% inhibition on HEV replication-related luciferase activity and less than 
50% cytotoxicity were selected (Supplementary Table 1). Their antiviral effects were 
further investigated at lower concentration (5 µΜ) in the full-length HEV infectious 
model by quantifying the HEV RNA using qRT-PCR assay (Fig. 1C). In both models, 
deptropine showed the most potent anti-HEV effects and thus was subjected to 
further detailed study. 
3.2. Deptropine Inhibits HEV in Multiple Cell Models 
Since HEV can cause a wide range of extrahepatic manifestations, we further 
validated the antiviral effect in several other cell models, including hepatic and 
nonhepatic cell lines. In line with the results observed in Huh7.5 cell model (Fig. 2A), 
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deptropine dose-dependently inhibited HEV replication in HEK293T (Fig. 2B) and 
Hep3B cells (Fig. S2A). Of note, in the Hep3B cell model, treatment with 5 µM 
deptropine potently inhibits HEV without affecting cell viability, excluding the antiviral 
effect of deptropine is through nonspecific cytotoxicity. The 50% inhibition and 
cytotoxicity (IC50 and CC50) concentrations of deptropine were 2.89 µM and 12.20 
µM in Huh7.5 cells, and 0.84 µM and 18.64 µM in HEK293T cells. Interestingly, 
genotype 1 HEV replicon is more sensitive to deptropine with an IC50 of 0.49 µM in 
Huh7.5 cells (Fig. 2C). The anti-HEV effect of deptropine was further verified by the 
re-infection assay (Fig. S2E). In addition, we found that deptropine significantly 
reduced the secretion of HEV into the supernatant (Fig. S2F). 
We next examined the effect of long-term treatment as described previously (Qu et 
al., 2017). Treatment with 5 µM deptropine dramatically reduced HEV viral RNA by 
80% after 39 days, and this effect was further confirmed at ORF2 protein level (Fig. 
2D). We further evaluated whether deptropine has a broad antiviral activity and found 
that deptropine potently inhibits HCV (Fig. S2C) but not rotavirus (Fig. S2D) 
replication. 
3.3. Histamine H1 Receptor Is Dispensable for the Anti-HEV Activity of 
Deptropine  
Because deptropine is a well-characterized histamine H1 receptor antagonist, we 
investigated whether this receptor is involved in its anti-HEV effect. We found that the 
expression of the H1 receptor was hardly detectable in both Huh7.5 and 293T cells 
(Fig. S3A), which is consistent with a previous study showing that Huh7.5 cells are 
deficient of this receptor (Pietschmann, 2017). Diphenhydramine, another H1 
antagonist (Fig. 3A), exerted no inhibitory effect on HEV in both Huh7.5 and 293T 
9 
 
cells (Fig. 3B). Chlorcyclizine HCl (CCZ), an H1 antagonist that has been shown to 
block HCV entry (He et al., 2015), also could not inhibit HEV (Fig. 3C and Fig. S3B), 
or HCV replication in a subgenomic replicon model (Fig. S3B). These results 
collectively suggest that the inhibitory effect of deptropine on HEV replication is likely 
dispensable of H1 receptor-mediated pathway.  
Since we have detected the expression of other histamine receptors to some extent, 
we performed a competition assay by co-incubating deptropine with histamine in the 
replicon model to assess the possible involvement of these receptors. We found that 
histamine has no effect on either HEV replication or deptropine-induced inhibition of 
HEV replication. Surprisingly, in the infectious model, histamine was able to inhibit 
HEV and slightly attenuated the anti-HEV effect of deptropine (Fig. 3D). Taken 
together, these results indicate that deptropine potently inhibits HEV replication 
independent of the histamine signaling, whereas we do not fully exclude that the 
histamine signaling may interfere with the other steps of HEV life cycle, such as viral 
entry. Because benztropine, a chemically similar drug with deptropine (Cui et al., 
2017), has been shown to exert its effect through alpha-7 nicotinic receptor (α7 
receptor) and expression of this receptor has been reported in hepatocytes (Wu et al., 
2015). This provoked us to investigate the possible role of α7 receptor in the anti-
HEV effect of deptropine. However, we found that the expression of this receptor is 
very low in Huh7.5 cells (Fig. S3C). In addition, α-bungarotoxin, the alpha-7 nicotinic 
receptor antagonist, has no effect on HEV RNA level and the anti-HEV effect of 
deptropine is not affected by the alpha-7 nicotinic receptor agonist nicotine (Fig. S3C), 
suggesting a α7 receptor-independent antiviral mechanism of deptropine.  
3.4. Deptropine Inhibits HEV in an NF-κB-dependent Manner 
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NF-κB plays a central role in promoting the expression of genes involved in 
inflammation and is activated in various viral infections (Tai et al., 2000). Moreover, 
the H1 antagonists are shown to inhibit NF-κB activity (Roumestan et al., 2008). We 
thus sought to investigate the potential role of NF-κB signaling in the deptropine-
mediated anti-HEV effect. A lentiviral vector expressing the firefly luciferase gene 
under control of the NF-κB promoter was transduced into Huh7.5 cells. We found that 
inoculation of HEV particles significantly activates the NF-κB transcription activity, 
which correlates with enhanced viral replication (Fig. 4A). In contrast to the potent 
NF-κB activator TNFα, treatment with deptropine significantly inhibited the NF-κB 
transcription activity (Fig. 4B). Supplementation with TNFα significantly attenuated 
the inhibitory effects of deptropine on NF-κB and anti-HEV activity (Fig. 4C), 
suggesting the possible involvement of NF-κB in the anti-HEV action of deptropine. 
To further evaluate the role of NF-κB on HEV replication, we tested additional 
compounds targeting NF-κB activity. The NF-κB activators, including betulinic acid 
and calcimycin, significantly inhibit HEV replication, whereas BAY11-7085 has no 
effect on HEV replication (Fig. S5). 
To further confirm the involvement of NF-κB in the antiviral effect of deptropine, wild 
type (WT), NF-κB knockout (NF-κB-/-) mouse embryonic fibroblasts (MEF) cells were 
used (Zhou et al., 2015). An decreased HEV RNA was observed in the NF-κB -/- 
MEF cells incubated with culture medium containing HEV particles compared with its 
wild type, suggesting a supportive role of NF-κB for HEV replication. Importantly, the 
anti-HEV effect of deptropine was completely abolished in the NF-κB-/- MEF cells 




Activator protein 1 (AP-1) transcription activity is closely related to NF-κB activity and 
has also been reported to be upregulated upon viral infection. We found that HEV 
slightly increased AP-1 activity (Fig. S4A) and deptropine could inhibit AP-1 activity 
(Fig. S4B). Moreover, associated with the obtained results that histamine could 
partially reverse the antiviral effect of deptropine in the HEV infectious model (Fig. 
3D), the inhibitory effects of either AP-1 or NF-κB transcriptional activity by 
deptropine was also partially attenuated after adding histamine (Fig. S4C).  
3.5. Caspase Activity Is Required for the Anti-HEV Effect of Deptropine  
It has been reported that activation of NF-κB signaling negatively regulate apoptosis 
by increasing the expression of anti-apoptotic genes, such as survivin, which function 
mainly by binding to active caspase 3/7 (Moghoofei et al., 2019). We found that the 
loss of NF-κB signaling dramatically abolished the increase of caspase 3/7 activity 
induced by deptropine (Fig. 4D). Concurrently, the expression of survivin was 
significantly reduced after treatment with deptropine (Fig. 4D). 
Caspase activity is well-recognized for regulating viral infection. We found that 
deptropine significantly elevated cellular caspase 3 and 7 activity (Fig. 5A), 
accompanied with a low level of apoptosis induction (Fig. S6A). Interestingly, HEV 
infection further augments the induction of caspase activity by deptropine (Fig. 5A). 
Importantly, co-incubation with Z-VAD-FMK, a general caspase inhibitor, attenuated 
the caspase induction and anti-HEV activity of deptropine. Similar results were 
observed in the combination of TNFα with Z-VAD-FMK (Fig. 5B). Moreover, in line 
with the results of histamine on HEV (Fig. 3D), treatment with histamine for 48 hours 
significantly increased the caspase activity and decreased the activation of caspase 
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induced by deptropine (Fig. 5C). These data suggest the requirement of caspase 
activity for the anti-HEV effect of deptropine.  
Interestingly, we found that in the presence of caspase 3 inhibitor, treatment with 
deptropine even decreased the cellular caspase 3 and 7 activity (Fig. 5C), and this is 
accompanied by the increase of HEV RNA when deptropine was added in 
combination with caspase 3 inhibitor (Fig. 5D). Furthermore, treatment with other 
caspase inhibitors also robustly abolished the anti-HEV effect of deptropine, 
suggesting a general role of caspase-mediated anti-HEV effect of deptropine. 
Unexpectedly, we found that all the caspase inhibitors significantly reduced HEV 
RNA without affecting cell viability (Fig. S6B and S6D), indicating the basal caspase 
activity may support HEV replication. Lastly, unlike the effects on HEV, caspase 
inhibition barely reverse the effect of deptropine on HCV, suggesting a specific role of 
caspase mediated anti-HEV effect of deptropine (Fig. S6C). Taken together, these 
data suggest that the basal caspase activity may support HEV replication; however 
the deptropine-induced caspase activation may contribute to its anti-HEV effect. 
3.6. Genetic Silencing of RIPK1 Restricts HEV Replication and Abolishes the 
Anti-HEV Effect of Deptropine 
RIPK1 is positioned at the center of cell-fate ‘decisions’ by modulating the crosstalk 
between NF-κB and caspase activity (Oeckinghaus et al., 2011). We examined the 
potential involvement of RIPK1. We found that gene silencing of RIPK1 significantly 
inhibited HEV replication (Fig. 6A and 6B). Importantly, loss of RIPK1 completely 
blocked the anti-HEV effect of deptropine (Fig. 6C). The kinase activity of RIPK1 is 
essential in promoting apoptosis (Newton, 2015). Consistently, we found that 
deptropine robustly induced phosphorylation of RIPK1 and the phospho-PIPK1 is 
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remarkably decreased in the presence of caspase 3 inhibitor (Fig. 6D). These results 
indicate that the kinase activity of RIPK1 is essential in caspase-mediated anti-HEV 
effect of deptropine (Fig. 5D). 
3.7. Deptropine Antagonizes the Anti-HEV Effects of IFNα, But Synergizes 
Ribavirin  
Since IFNα and ribavirin are clinically used for treating chronic HEV patients, we 
evaluated their combinatory effects with deptropine. We found that deptropine 
exhibited antagonistic effect with IFNα (Fig. 7A), but synergistic effect with ribavirin 
(Fig. 7B). To explore the potential mechanistic explanations, we evaluated their 
effects on NF-κB activity. Supportively, we found that IFNα but not ribavirin exerted 
strong inhibitory effect on NF-κB activity (Fig. S7A). Although it has been reported 
that IFNα is able to induce caspase activation (Apelbaum et al., 2013), no increased 
caspase 3 and 7 activity was observed after treatment with IFNα for 48 hours in 
Huh7.5 cells (Fig. S7B). Furthermore, the anti-HEV effect of IFNα was not affected in 




Ribavirin monotherapy or in combination with PEG-IFNα is effective for chronic 
hepatitis E. However, treatment failure frequently occurs in a subset of patients 
(Debing et al., 2014). More importantly, a large number of patients, especially acutely 
infected pregnant women, are not eligible for this treatment. Drug repurposing allows 
rapid identification of new treatment from existing drugs that can dramatically speed 
up the clinical implementation. For example, ribavirin was initially approved for 
treating HCV but now is used as off-label treatment for HEV (Kamar et al., 2014). 
Distinct from the empirical approach, recent development of high-throughput drug 
screening technology has enabled unbiased identification of potential treatment from 
a large set of compounds. For example, screening of the FDA-approved drug 
libraries has led to the discoveries of potential therapies for Ebola virus, HCV and 
Zika virus infections. Herein, by screening a library of FDA-approved drugs, we found 
that a histamine H1 receptor antagonist deptropine potently inhibits HEV.  
Among the four histamine receptors (H1, H2, H3, and H4), H1 receptor is the main 
regulator of acute inflammation. Accordingly, most of the H1 antagonists  function as 
inverse agonists, leading to the relief of inflammation. An increased release of 
histamine from hepatic mast cells has been reported in hepatitis (Francis and 
Meininger, 2010). In this study, we found that supplementation with histamine has no 
effect on HEV replication in a subgenomic replicon that only mimics viral replication 
due to the lack of ORF2 capsid protein. However, histamine dose-dependently 
inhibits HEV infection in the infectious model with the full life-cycle, suggesting 
multiple interaction between HEV and histamine signaling. Previous studies have 
reported the inhibition of the entry of Ebola/Marburg virus (Cheng et al., 2015) and 
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HCV by H1 antagonists (Cheng et al., 2015). However, the antiviral effect of H1 
antagonist seems not require the H1 receptor (He et al., 2015). 
It has been reported that H1 antagonist could regulate the transcription factor NF-κB 
and caspase activity (Haas et al., 2018). This coordinately modulates the 
inflammatory microenvironment, resulting in enhancement or antagonism of the host 
antiviral defense. Increased NF-κB activity induces the transcription of genes 
promoting cell survival (Schmitz et al., 2014). On the contrary, activation of caspases 
is thought to counteract the pro-survival role of NF-κB. Of note, RIPK1 actively 
modulates the crosstalk between caspase and NF-κB signaling. Viruses have 
developed sophisticated strategies to evade host defense. Dengue virus and 
influenza virus activate NF-κB to support their replication (Cassens et al., 2003; 
Nimmerjahn et al., 2004). For hepatitis viruses, HCV was reported to increase NF-kB 
and AP-1 activation, which was further augmented by the presence of hepatitis B 
virus X protein (Kanda et al., 2006). We found that inoculation of HEV particles 
increases NF-κB activity. In addition, we have demonstrated that the basal NF-κB 
activity serves as a supportive factor for HEV replication. In patients, liver biopsies 
from pregnant women infected with HEV who developed fulminant hepatic failure 
(FHF) have higher transcriptional activity of NF-kB compared to those from 
nonpregnant women or pregnant women infected HEV without development of FHF 
(Prusty et al., 2007). Consistent with a recent study (Lenggenhager et al., 2017), we 
found that the presence of HEV ORF2 protein in cell nucleus (Fig. S4D). We thus 
speculate the possibility that nuclear ORF2 may play a role in HEV-mediated 
regulation of NF-κB transcription. In contrast, HEV ORF3 protein has been reported 
to suppress TLR3-induced NF-κB activity (He et al., 2016). Thus, the interactions of 
HEV with NF-κB are multifaceted, requiring further clarification.  
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There are mutual interactions between caspase activation and viral infection 
(Saelens et al., 2001). Several viruses express proteins targeted by the caspase 
protease and cleavage of these proteases results in inhibition of apoptosis (Connolly 
and Fearnhead, 2017; Richard and Tulasne, 2012). HCV infection induces caspase 
activation to cleave the viral nonstructural protein 5A, which subsequently 
translocates to nucleus to enhance the transcription of several NF-κB target genes to 
inhibit apoptosis (Jiang et al., 2015). However, some viruses can benefit from 
caspase activation. Influenza A virus and papillomaviruses require caspase activity 
for efficient replication (Moody et al., 2007; Ozawa et al., 2007). Recent evidence 
indicate that HEV infection is associated with caspase activation (Yang et al., 2018). 
The release of cytochrome c from mitochondria is a key event to activate caspase. A 
previous study has reported that HEV prevents the release of cytochrome c induced 
by staurosporine, suggesting a negative regulation of caspase activation by HEV 
infection (Moin et al., 2007). Consistently, our recent study has shown that HEV is 
able to block ionomycin-induced MPTP opening (Qu et al., 2019), which is a vital 
process to activate caspase. In this study, we found that blocking of the excessive 
caspase activation induced by deptropine could reverse its anti-HEV effect. 
Counterintuitively, the basal caspase activity may support HEV replication as 
inhibition of caspase activity leads to reduction of HEV RNA.  
RIPK1 is a key determinant of cell survival or death through its scaffold properties or 
kinase activity, respectively (Kondylis and Pasparakis, 2019; Lafont et al., 2018). This 
essentially involves the crosstalk between caspase and NF-κB signaling. We found 
that gene silencing of RIPK1 dramatically inhibits HEV replication. Importantly, loss of 
RIPK1 abolished the anti-HEV effect of deptropine. Interestingly, deptropine robustly 
induces RIPK1 phosphorylation and this effect can be inhibited by caspase inhibitor. 
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These results have indicated the importance of RIPK1 in mediating the anti-HEV 
action of deptropine. However, the exact role of the scaffold property or/and kinase 
activity of RIPK1 in this process remains to be further clarified.  
In summary, we have identified deptropine as a potent anti-HEV agent. The anti-HEV 
activity of deptropine involves the NF-κB-RIPK1-caspase axis, but the detailed 
working mechanisms remain to be further investigated. Given that deptropine is a 
safe and cheap drug that has been widely used to treat asthmatic symptoms in the 
clinic, it is warranted to evaluate its anti-HEV efficacy in future clinical studies. By 
implementation of these results in the clinical setting, this may revolutionize the 
current management of hepatitis E and represent as a milestone in response to the 
global call towards the elimination of hepatitis B and C by 2030. 
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Fig. 1. Screening of a drug library identified deptropine as a potent inhibitor of 
HEV replication.  
(A) Schematic illustration of the screening strategy. The primary screening was 
conducted in the HEV replicon model, and the effects of selected primary hits was 
further evaluated in the HEV infectious model. (B) Huh7.5 cell based HEV replicon 
model was treated with 1,280 compounds with 95% of FDA-approved drugs at 10 µM. 
The HEV-related Gaussia luciferase value (HEV RLU) was measured 48 hours post-
treatment. Points represent the relative HEV replication for each drug. (C) qRT-PCR 
analysis of HEV viral RNA level in Huh7.5 cell based HEV infectious model treated 
with the 38 selected drugs at 5 µM from the primary screening for 48 hours. Data 
were normalized to the DMSO vehicle control (set as 1) and presented in dot plots. 
The black dot pointed by an arrow represents deptropine. 
 
Fig. 2. Deptropine inhibits HEV replication in multiple cell models. 
(A) Huh7.5 cell based HEV replicon and infectious models were treated with 
indicated concentrations of deptropine for indicated time period before the 
measurement of HEV, and the untreated (CTR) group serve as control (set as 1) (n = 
8). (B) 293T cell based HEV replicon and infectious models were treated with 
indicated concentrations of deptropine for indicated time period before the 
measurement of HEV, and the untreated (CTR) group serve as control (set as 1) (n = 
8). (C) The 50% inhibitory concentration (IC50) and 50% cytotoxic concentration 
(CC50) of deptropine against HEV replication in indicated cell lines were calculated 
using GraphPad Prism 5 software (n = 4-8). The IC50 of deptropine against genotype 
1 (GT1) HEV replication were calculated using GraphPad Prism 5 software (n = 5). 
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(D) Treatment with 5 µM deptropine for 39 days retains anti-HEV effect in Huh7.5 cell 
based HEV infectious model. The untreated (CTR) group serve as control (set as 1) 
(n = 2). Western blot analysis of HEV capsid ORF2 protein levels in the Huh7.5 cell 
based HEV infectious model treated with deptropine for 39 days. Data are presented 
as means ± SD. (*P < 0.05; **P <0.01; ***P < 0.001). 
 
Fig. 3. The anti-HEV effect of deptropine is dispensable of the histamine 
pathway 
(A) Chemical structures of the indicated compounds. (B) qRT-PCR analysis of HEV 
RNA level in the Huh7.5 and 293T cell based HEV infectious models treated with 
indicated concentrations of diphenhydramine for 48 hours. The untreated group 
serve as control (set as 1) (n = 4). (C) qRT-PCR analysis of HEV RNA level in the 
Huh7.5 cell based HEV infectious model treated with indicated concentrations of 
chlorcyclizine HCl (CCZ) for 48 hours. The untreated group serve as control (set as 1) 
(n = 6). (D) Co-incubation of indicated concentrations of deptropine and histamine in 
Huh7.5 and 293T for 48 hours before testing the HEV-related luciferase. The 
untreated group serve as control (set as 1) (n = 5-6). Co-incubation of indicated 
concentration of deptropine and histamine in Huh7.5 cell based HEV infectious 
model for 48 hours before measurement of HEV RNA by qRT-PCR assay. The 
untreated group serve as control (set as 1) (n = 4). The above data are means ± SD. 





Fig. 4. The anti-HEV effect of deptropine requires its inhibition on NF-κB 
activity. 
(A) The Huh7.5 cell based NF-κB reporter model was inoculated with culture medium 
containing HEV particles. After 3 days inoculation, the medium was changed to 
normal cell culture medium without HEV particles. TNFα treatment serves as a 
positive control. The untreated mock group serves as control (set as 1). The NF-κB 
luciferase was measured at indicated time points (n = 8-12). qRT-PCR analysis of the 
HEV RNA level in the mock group or HEV-infected group at indicated time points. 
The HEV RNA tested on 4, 5, 6 days are relative to the HEV RNA on day 3 (set as 1) 
(n = 4). (B) The Huh7.5 cell based NF-κB reporter model was treated with indicated 
agents for 24 hours before testing the NF-κB luciferase value. The untreated group 
serves as control (set as 1) (n = 6). (C) The Huh7.5 cell HEV infectious model was 
treated with indicated agents for 24 hours before testing NF-κB luciferase value and 
for 48 hours before testing HEV RNA level by qRT-PCR assay. Data in deptropine-
treated group were presented relative to the untreated control group (set as 1). Data 
in the combination group of deptropine with TNFα were presented relative to TNFα-
solely treated group (set as 1) (n = 6-8). (D) The wild type (WT) and NF-κB knockout 
(NF-κB -/-) mouse embryonic fibroblast (MEF) cells were treated with deptropine, and 
the HEV RNA level were measured by qRT-PCR assay after 48 hours treatment. The 
untreated WT group serves as control (set as 1) (n = 8). The wild type (WT) and NF-
κB knockout (NF-κB -/-) mouse embryonic fibroblasts (MEF) cells were inoculated 
with HEV particles (1.5×106 HEV RNA copies/ml) and treated with indicated agents. 
Data in WT MEF was presented relative to the non-treated WT group (set as 1). Data 
in NF-κB -/- MEF were presented relative to the untreated NF-κB -/- MEF group (set 
as 1) (n = 6). Huh7.5 cells were treated with indicated concentrations of deptropine. 
26 
 
The RNA level of Survivin was measured by qRT-PCR assay after 48 hours 
treatment. The untreated group serves as control (set as 1) (n = 6). The above data 
are means ± SD. (*P < 0.05; **P <0.01; ***P < 0.001). 
 
Fig. 5. Inhibition of caspase activity reverses the anti-HEV effect of deptropine 
(A) Huh7.5 cell based HEV infectious model was treated with indicated agents for 48 
hours before subjected to caspase 3/7 activity analysis. The untreated mock group 
serves as control (set as 1) (n = 8). (B) Huh7.5 cell based HEV infectious and 
replicon models were treated with indicated agents, alone or in combination. After 48 
hours treatment, samples were subjected to qRT-PCR analysis. Data in deptropine or 
TNFα solely treated groups were presented relative to the untreated group (set as 1). 
Data in the combination group of deptropine or TNFα with Z-VAD-FMK were 
presented relative to Z-VAD-FMK solely treated group (set as 1) (n = 7-9). (C) 
Huh7.5 cells were treated with indicated agents for 48 hours before being subjected 
to caspase 3/7 activity analysis. The untreated group serves as control (set as 1) (n = 
4-5). (D) Huh7.5 cell based HEV infectious model was treated with indicated agents, 
alone or in combination. After 48 hours treatment, samples were subjected to qRT-
PCR analysis. Data in deptropine solely treated group were presented relative to the 
untreated group (set as 1). Data in combination group of deptropine with caspase 1 
or caspase 3 were presented relative to caspase 1 or caspase 3 solely treated group 
(set as 1) (n = 6-9). Huh7.5 cell based HEV infectious model was treated with 
indicated agents, alone or in combination. After 48 hours treatment, samples were 
subjected to qRT-PCR analysis. Data in deptropine solely treated group were 
presented relative to the untreated group (set as 1). Data in combination group of 
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deptropine with caspase 8 or caspase 9 were presented relative to caspase 8 or 
caspase 9 solely treated group (set as 1) (n = 5-10). The above data are means ± SD. 
(*P < 0.05; **P <0.01; ***P < 0.001). 
 
Fig. 6. The anti-HEV effect of deptropine is dependent of RIPK1 
(A) Western blot analysis of RIPK1 expression in Huh7.5 based HEV infectious 
model transduced with different lentiviral shRNA vectors targeting RIPK1 (shRIPK1) 
or scrambled control (shCTR). (B) The RIPK1 expression level and HEV viral RNA 
level were analyzed by qRT-PCR in the stable RIPK1 knockdown or scramble control 
cells (n = 4-6). The data are means ± SD and presented relative to shCTR (shCTR, 
set as 1) (*P < 0.05; **P <0.01). (C) shRIPK1 or shCTR cells were incubated with or 
without 10 µM deptropine for 48 hours before measurement of HEV RNA. Data in 
shCTR group were presented relative to the untreated shCTR group (shCTR, set as 
1). Data in shRIPK1 group were presented relative to the untreated shRIPK1 group 
(shRIPK1, set as 1) (n = 3-6). The data are means ± SD. (***P < 0.001). (D) Huh7.5 
cells were treated with 10 µM deptropine and 100 µM caspase 3 inhibitor alone or in 
combination for 48 hours. The levels of indicated proteins were analyzed by western 
blot assay. 
 
Fig. 7. The combination of deptropine with IFN-α and ribavirin results in 
antagonistic or synergistic effect against HEV.  
The antiviral effects of deptropine in combination with IFN-α (A) or ribavirin (B) was 
analyzed by the MacSynergyII model. The three-dimensional surface plot represents 
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the differences (within 95% confidence interval) between actual experimental effects 









• Screening of a library containing over 1,000 FDA-approved drugs identified 
deptropine as a potent inhibitor of HEV.  
 
• Deptropine, a classical histamine H1 receptor antagonist, has been widely used 
to treat asthmatic symptoms. 
 
• The anti-HEV activity of deptropine appears dispensable of the histamine 
pathway. 
 
• Deptropine exhibited antagonistic effect with IFNα, but synergistic effect with 
ribavirin. 
